Adipose-derived stem cells (ASCs) are considered a great alternative source of mesenchymal stem cells (MSCs). Unlike bone marrow stem cells (BMSCs), ASCs can be retrieved in high numbers from lipoaspirate, a by-product of liposuction procedures. Given that ASCs represent an easily accessible and abundant source of multipotent cells, ASCs have garnered attention and curiosity from both scientific and clinical communities for their potential in clinical applications. Furthermore, their unique immunobiology and secretome are attractive therapeutic properties. A decade since the discovery of a stem cell reservoir residing within adipose tissue, ASC-based clinical trials have grown over the years around the world along with assessments made on their safety and efficacy. With the progress of ASCs into clinical applications, the aim towards producing clinical-grade ASCs becomes increasingly important. Several countries have recognised the growing industry of cell therapies and have developed regulatory frameworks to assure their safety. With more research efforts made to understand their effects in both scientific and clinical settings, ASCs hold great promise as a future therapeutic strategy in treating a wide variety of diseases. Therefore, this review seeks to highlight the clinical applicability of ASCs as well as their progress in clinical trials across various medical disciplines.
Introduction
Lipoaspirate, an otherwise by-product of plastic surgery, has been shown to contain a putative source of stem cell population within the heterogeneous stromal cells of adipose tissue. ASC exhibits properties similar to mesenchymal stem cell (MSC), an adult stem cell type (Ref. 3) . According to the standard criteria set by the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy, MSC must fulfil the following criteria: (i) plasticadherent in standard culture conditions; (ii) express CD105, CD73 and CD90, but negative for the surface expression of CD45, CD34, CD14, CD79 and HLA-DR; and (iii) able to differentiate into osteoblasts, adipocytes and chondroblasts in vitro (Ref. 4) .
For many years, bone marrow was considered as the major source of MSCs. However, traditional bone marrow procurement of MSCs is invasive, painful and inefficient because of low cell yield, which necessitates a subsequent ex vivo expansion step. A significant advantage of ASCs as an adult stem cell source, is that while bone marrow stem cells (BMSCs) are a rare population within the stromal cells, constituting only~0.002%, ASCs constitute up tõ 2% within the stromal vascular fraction (SVF) (Ref. 5) . Under appropriate conditions, ASCs have the ability to differentiate into multiple mesodermal lineages cell types, such as adipocytes, fibroblasts, myocytes, osteoblasts and chondrocytes. Furthermore, studies have shown that ASC has the ability to transdifferentiate into nonmesodermal cell types, such as neuronal cells, hepatocytes, endothelial cells and cardiomyocytes (Ref. 6) .
Undeniably an attractive cell source for therapeutic applications, to date, clinical trials with ASCs have increased over years with assessments being made on safety and efficacy of ASC therapies across various medical disciplines. A decade since the discovery of ASCs, this paper seeks to provide a timely review of the advancement of ASCs in therapeutic use. The review highlights the clinical applicability of ASCs and its progress in various medical disciplines, as well as an outlook of the ASC therapy field.
The aim towards clinical-grade ASCs Manual isolation and culture of ASCs
Adipose tissue consists of mature adipocytes and other heterogeneous cell populations, which upon isolation are termed SVF. The SVF is composed of preadipocytes, fibroblasts, vasculature cells, immune cells and most importantly, ASCs (Ref. 7) .
A typical manual isolation procedure of ASCs involves enzymatic digestion of adipose tissue, followed by centrifugation to separate floating mature adipocytes from the ASC-containing SVF in the pellet fraction (Ref. 1) . SVF can be further passaged in expansion medium to isolate more homogeneous ASCs. Given that the multiple laboratory steps involved in the manual isolation of ASCs may have considerable effects on achieving clinical-grade ASCs, several groups have worked independently to develop and refine the procedures needed to isolate ASCs.
For clinical translation of isolated ASCs, it is essential that the collagenase used in liberating regenerative cells from adipose tissue are Good Manufacturing Practice (GMP)-manufactured and animal sources-free (e.g. Celase ® ) (Ref. 8) , hence not posing risk of infectious diseases such as bovine spongiform encephalopathy/transmissible spongiform encephalopathy (BSE/TSE) to human recipients. Xeno-free collagenases have shown to have a similar efficiency in yield and proliferation of isolated cells as research-grade collagenases (Ref. 9) . Alternatively, the conventional protocol can be modified to omit the use of enzyme in the ASC isolation process. Bianchi et al. (Ref. 10) have undertaken a nonenzymatic method of digestion of adipose tissue, by using mild mechanical forces to isolate a nonexpanded and ready-to-use fat product. According to the authors, ASCs isolated from this method exhibited a higher degree of vasculogenic potential. Shah et al. (Ref. 11) demonstrated the use of manual vigorous shaking by hand and obtained ASCs that displayed enriched level of messenchymal markers and reduced level of haematopoietic markers, although there was reduction in yield. On the other hand, other groups have investigated the use of blood and saline portion of lipoaspirates as an enzymefree source of ASCs, and isolated ASCs with differentiation and immunophenotypic characteristics comparable to those by enzymatic digestion, although the yield will need to be further optimised (Refs 12, 13) . If these novel methods are able to demonstrate similar levels in ASC yield, proliferation and differentiation as the enzymatic isolation protocols, it may eventually pave the way for using minimally manipulated ASCs in clinical trials.
Centrifugation is essential for concentrating SVF and ASCs, but excessive centrifugation may also lead to cellular damage. Hence, several groups have investigated an optimal centrifugal force (Refs 14, 15) and currently, the recommendation is 1200 g for 5 min as an optimal centrifugation rate for both short-and long-term adipose transplantation (Ref. 16) .
Another probable variability is the type of medium used for the culture expansion to achieve homogeneous ASCs. The classical basal medium used for ASCs are usually Minimum Essential Media (MEM), Dulbecco's Modified Eagle Medium (DMEM), Roswell Park Memorial Institute (RPMI)-1640 and DMEM:F12 (Ref. 7) . One study showed that the proliferation and differentiation of ASCs varied according to the type of culture medium used (Ref. 17) . Furthermore, the expression of genes in the cultured ASCs differed when different media were adopted (Ref. 17) . Therefore, the choice of an optimal medium for clinical trials using cultured ASCs would be one major consideration.
In order to achieve a high cellular dose of MSCs suitable for clinical trials, it is necessary to expand cells on the basal medium supplemented with serum. Typically, the standard in vitro cell expansion techniques utilise fetal bovine serum (FBS) to provide the cell with essential nutrients, attachment factors and growth factors (Ref. 18 ). However, serum of animal origins may pose several potential safety issues on patients, including risk of possible infections (Ref. 19 ) and severe immune responses (Ref. 20) . In an effort to overcome the potential risk of introducing xenogeneic antigens into patients, human serum has been proposed as an alternative replacement for FBS. Examples of human serum derivatives include allogenic AB serum (Ref. 21) , thrombinactivated platelet-rich plasma (Ref. 22 ) and human platelet lysate (Refs 21, 23, 24) . Studies using such human serum derivatives have shown comparable or superior results to FBS in supporting proliferation and differentiation of ASCs (Ref. 21 ). However, limited availability and batch-to-batch variability of human serum are potential barriers for large-scale production of clinical-grade ASCs (Refs 7, 25). Alternatively, a serum-free medium could be an optimal option for standardisation of cell culture as it provides defined and controlled culture conditions that are highly specific to cell types in terms of its stimulation and growth (Ref. 18 ).
Existing studies have reported promising results of serum-free medium (Refs 26, 27, 28), although further pre-clinical safety and efficacy studies are required to test these culture formulations.
Another major challenge of producing clinicalgrade cells is having a reliable, reproducible and safe method of preparing cells for administration to patients. The in vitro culturing and expansion process of ASCs still lacks an established and standardised protocol (Ref. 29) . Hence, the identification of an optimal basal medium and serum replacer will be an important step forward for both the implementation of a GMP and large-scale production of clinical-grade ASCs for therapeutic applications.
Industrial approach to clinical-grade ASCs
In order to achieve production of clinical-grade cells that avoids inherent contamination risk and intra/inter-operator variability associated with traditional techniques, scientists, engineers and clinicians have taken collaborative efforts to develop a sophisticated bioreactor-based system. The bioreactor-based device offers an attractive device that could possibly provide a standalone, fully automated and closed system that facilitates complicance to GMP in manufacturing ASCs aimed for therapeutic use (Ref. 30 and Sepax-based automated isolation system (Ref. 31 ).
An example of such integrated systems is Celution ® system developed by Cytori Therapeutic Inc (San Diego, CA, USA; see footnote 1). In this system, adipose tissue is first introduced into the device and washed to remove debris. Subsequently, it is enzymatically digested to release mononuclear cells from adipose tissue and transferred to a centrifugation compartment for concentration of SVF/ASCs. The end-product is ready to be administered to patients. The whole system mimics the manual isolation procedures of SVF/ ASCs, and reduces the processing time to 1-2 h. The integrated system also means that the whole process can be carried out in clinical setting without the need for highly trained laboratory technicians. Freshly isolated cells from such a system have been studied and analysed to be equivalent to those manually isolated (Ref. 32) .
The 
Clinical banking of ASCs
The enormous potential of ASCs in therapies could mark a foreseeable step towards clinical banking of ASCs in the near future (Refs 2, 34). In addition to storage of individual ASCs for autologous use, allogenic transplantation of MSCs that require a large cell number may also benefit from the development of stem cell banks, which cryopreserve cells from healthy donors. This will advance ASC therapies to 'off-theshelf' approaches that would allow stem cells to be available in a timely fashion under acute or chronic clinical settings (Ref. 34) . Therefore, the time is ripe now for establishment of cryopreservation methods and protocols to assure clinical-grade ASCs. Presently, many companies claim to provide banking of adipose tissue or ASCs. However, compliance with GMP guidelines for the entire process from cell collection to cryopreservation of ASCs remains questionable, especially since some of these companies are still awaiting approval from FDA 5 . Furthermore, existing cryopreservation protocols of adult stem cells still require further refinement to lower dependence on animal serum and potentially toxic cryoprotectant additives in the freezing and storage of cells (Refs 35, 36, 37) .
Heterogeneity of ASCs
Although clinical banking of ASCs may still be at an infant stage, it remains valuable to define harvesting sites, harvesting techniques and donor types for isolation of ASCs. Defining these variables will facilitate identification of ASC population optimal for cell therapies, thereby assuring consistent therapeutic results following the application of ASCs. The variables that may affect the yield and functionality of isolated ASCs can be broadly classified into two categories: namely (i) donor-dependent heterogeneity and (ii) intra-individual heterogeneity.
Donor Lastly, investigation into effects of the three main classical harvesting techniques of ASCs including resection, tumescent liposuction and ultrasound-assisted liposuction, has shown that the application of ultrasonic energy through cannula yields the lowest frequency of ASCs and has the most detrimental effects on quality of ASCs (Ref. 47) .
It is a challenge to clearly define effects of the donor-dependent and intra-individual heterogeneities on the yield, proliferation and differentiation of ASCs, as many of these epidemiological or experimental studies are performed on a relatively small sample size and with different methodological approaches. Moreover, adipose tissue depots are highly heterogeneous with many variables contributing to the yield and functionality of ASCs. Therefore, an ideal study should normalise for these multiple variables so as to determine causality between the two differences to be examined.
Legal and regulatory issues of cell therapy
Cell therapy has emerged as a novel strategy for treatment of numerous human diseases. (Table 2 ), but currently it has only seven clinical trials registered (Table 1) , likely attributed to the rigorous regulation of cell therapy by US FDA.
Most clinical studies on ASCs published thus far are not only limited in numbers, but the study designs of the ASC-based clinical trials performed till date also produced predominately lower levels of evidence according to the Oxford Centre for Evidence-Based Medicine 10 . For example, the majority of these published studies are case reports, anecdotal studies or phase I/II studies performed in a relatively small sample size. Nonetheless, the reported clinical studies have covered a wide variety of specialties and indicated that ASC or SVF administration has been well tolerated ( Table 3 ). The following subsections will categorise and summarise publications concerning the clinical use of ASCs and its outcomes in various areas of medical diseases.
Bone and cartilage repair
There are several case reports that examine the therapeutic potential of ASCs in healing skeletal defects in patients. One of the earliest report of using ASCs in regenerative medicine is the study done by Lendeckel et al. (Ref. 64) . A 7-year-old sustained calvarial fractures after a severe head injury. A surgical procedure was conducted to replant and fix cryopreserved calvarial fragments, following craniectomy. However, osteosynthesis plates loosened and significant bone resorption resulted in an unstable skull. To rectify the situation, a surgical procedure combining autologous SVF and bone grafts was proposed. Autologous SVF was isolated and subsequently, soaked with milled bone grafts. In addition, to keep the SVF cells in place, autologous fibrin glue was applied and mechanical fixation performed with resorbable macroporous sheets. Postoperative course healing was uneventful and 3 months later, computed tomography (CT) scan showed new bone formation and complete calvarial continuity after reconstruction. Hence, the outcome from the case report suggests that autologous SVF enhances the process of bone regeneration, together with bone graft serving as an osteoconductive scaffold, although it remains to be determined how much of the effect is due to autologous SVF.
Another study on skull restoration, was performed in Finland on four patients with cranial defects due to various conditions (Ref. 65 ). To create autologous bone for the repair of cranial defects, clinical-grade autologous ASCs cultured in a GMP facility were seeded on beta-tri-calcium phosphate (betaTCP) granules. Postoperatively, the surgical procedure was tolerated well by the patients and no adverse events reported. After 3 months to a year of follow-up, CT scans revealed satisfactory outcomes in ossification. Retrieved from web of knowledge on 25th November 2013. In the third case, Mesimaki et al. (Ref. 66 ) took a novel approach to repair craniofacial defects. The patient was 68 years old, with part of the hard palate in the mouth removed due to a large keratocyst. To address the issue of limited bone graft, ectopic bone was formed in a muscle-free flap region with GMP-grade ASCs combined with betaTCP and growth factor bone morphogenetic protein (BMP)-2. Subsequently, the construct was resected and transplanted to the maxillofacial defect. Four months after the surgical procedure, the implant integrated well into the bone site with normal palatal mucosa formation and provided enough structural stability for dental rehabilitation. Following the success of such a tissue-engineering triad approach, which includes ASCs with osteogenic potential, betaTCP as an osteogenic scaffold, and BMP growth factor to build a custom-made implant, more than 20 patients with craniomaxillofacial defects were similarly treated with positive results (Ref. 67) .
With approval of the KFDA, a team in Korea proceeded with ASC-based treatment of two patients with osteonecrosis of femoral heads (Ref. 68 ). The procedure included autologous SVF isolated from patient's abdominal, mixed with calcium chloride-activated autologous plateletrich plasma (PRP) and hyaluronic acid serving as the scaffold, and together this mixture was injected into the femoral head under ultrasonic guidance. Two weeks after the treatment, both patients reported significant reduction in hip pain, and post-procedure MRI showed changes that were consistent with bone regeneration. Neovascularisation at the necrotic site was speculated to support the regenerated tissues, but no bone biopsy was performed to further investigate the mechanism behind the efficacy.
The same team also reported a series of case studies that included the treatment of osteoarthritis with ASCs (Ref. Cytori Therapeutics has completed and reported data of two clinical studies, 'APOLLO' (Ref. 57) and 'PRECISE' (see Table 3 ) (Ref. 56 ). Both studies were prospective, placebocontrolled, double-blinded Phase I studies designed to assess safety and feasibility of ASCbased therapies for acute myocardial infarction (APOLLO) and chronic myocardial ischaemia (PRECISE). ASCs (also termed 'ADRCs') from all trial participants were processed at point-of-care with the Celution ® system, and administered to patients. Safety was measured by occurrence of major adverse cardiac or cerebral events (MACCE) and feasibility by monitoring cardiac function improvement. Results from both trials reported no adverse events directly related to the ASC therapies and suggested good efficacy consistent with their pre-clinical findings. Based on the results from APOLLO, in May 2011 Cytori initiated a multicenter, prospective, randomised, placebo-controlled phase IIb/III clinical trial that will assess the safety and efficacy of an intracoronary infusion of 2 doses of ASCs in up to 375 patients with ST-elevation myocardial infarction.
ASCs in peripheral vascular diseases (PVD)
Since several studies showed that ASCs are capable of secreting significant quantities of angiogenic (Refs 78, 79, 80, 81) or anti-apoptotic factors (Refs 80, 81), and transdifferentiating into endothelial cells (Refs 82, 83) or into pericytes essential for vascular stabilisation (Ref. 84) , it is conceivable that this cell source is valuable for PVD treatment. One published pilot study enrolled 15 patients with critical limb ischaemia due to either thromboangiitis obliterans or diabetic conditions. Subsequently, the patients were treated with intramuscular injection of autologous passaged ASCs. The study reported clinical improvement in 66.7% of the enrolled patients along with significant improvement in pain scores. Furthermore, digital subtraction angiography (DSA) performed 6 months from the treatment revealed new collateral vessel formation.
Soft tissue augmentation and reconstructive surgery ASCs as fillers in cosmetic and reconstructive surgery (Fig. 1) . CAL used in clinical studies is generally well tolerated by the patients and tends to achieve higher aesthetically acceptable results as compared to autologous fat grafting alone in controlled studies (Refs 15, 89) . The clinical reports of CAL are summarised in Table 4 .
The exact function of ASCs in CAL remains to be elucidated, although several mechanisms have been suggested. ASCs may play a role in promoting angiogenesis and graft survival, through their ability to differentiate into vascular endothelial cells and release angiogenic growth factors (e.g. vascular endothelial growth factor (VEGF)) in response to surgical injury, hypoxia or wound-healing process (Ref. 88 ). In addition, co-delivered ASCs may be prompted to differentiate into mature adipocytes, thereby constituting the transplanted fat (Ref. 88) .
Another novel strategy that shares the same principle of CAL to enrich ASC-poor fat is staged stem cell-enriched tissue (SET) injections. While CAL combines ASCs with aspirated fat ex vivo before injecting this mixture as a single construct to patients, SET involves injection of autologous ASCs into an area that was pregrafted with nonenriched fat just hours before. Although there is no clinical study comparing these two techniques thus far, two clinical studies using SET reported promising results with no adverse events (Refs 96, 97) .
Lastly, one study used mature adipocytes that were differentiated from autologous ASCs (ADIPOCELL) to treat 31 patients with depressed scars (Ref. 95 ). The long-term followup (1 year) found maintenance of volume that was increased from the therapy. Therefore, it appears that mature adipocyte grafting may be a good alternative to traditional fat grafts for volume augmentation.
ASCs in wound healing
The role of ASCs in wound healing has been validated in preclinical studies done with various delivery methods (Refs 98, 99, 100, 101, 102). ASCs appear to promote wound healing through multiple mechanisms such as their direct differentiation into dermal fibroblasts and keratinocytes, and their trophic support for regenerating tissues (Refs 103, 104) . However, the clinical application of ASCs in wound healing is still at its preliminary stage and With both safety and efficacy results reported in phase I and II studies, the group had initiated and completed a phase III study, in line with an application for marketing authorisation of the ASC therapy in fistula repair. However, the study was unable to provide statistically significant results on the efficacy of ASCs when compared to the control group with fibrin glue treatment. Notably, the authors attributed the inconclusive results to the likely variability of methods and protocols introduced from the multi-centre nature of the study. Vanikar et al. (Ref. 122) reported improved insulin sensitivity in 11 Type 1 diabetic patients who were co-infused with insulin-secreting cells derived from ASCs and cultured bone marrow cells. This cell mixture derived from the xeno-free workflow was infused into patients via omental vein. In the 23 months follow-up, all patients were successfully treated, showing raised serum c-peptide level, less exogenous insulin requirement, decreased HbA1c level and absence of diabetic ketoacidosis events. While the exact mechanism behind the therapeutic effects remains to be elucidated, this study may present a novel potential insulin replacement therapy based on ASCs.
Diabetes mellitus

Perspective
Since discovery of a rich source of MSCs in adipose tissue, ASCs and SVF have made progressive advances in the clinical realm. Notwithstanding the fact that till date, the safety and efficacy evidence of ASC therapy is limited to anecdotal studies or phase I/II clinical trials, ASC therapy represents a promising therapeutic strategy to treat various diseases. However, it is crucial that any possibilities of unwanted and unexpected effects are critically assessed before embarking on a novel ASC-based therapy.
Some concerns have been raised regarding properties of ASCs to promote tumour growth. While the pro-angiogenic, anti-apoptotic and immunomodulatory properties of ASCs are attractive therapeutic aspects of ASCs, these may also act individually or together to support tumour growth (Ref. 127) . Several articles have extensively reviewed the tumourigenic potential of ASCs and highlighted the striking contrast of results obtained from various experimental studies (Table 7) (Refs 127, 128) . Many experimental models fail to faithfully recapitulate the complexity of tumour microenvironment (Refs 127, 128) . Therefore, a definite conclusion on pro-tumourigenic effect of ASCs is still pending.
Furthermore, clinical studies with ASCs have so far not reported the speculated theoretical risk of ASCs in promoting tumour. Nevertheless, currently it may be too early to judge as the follow-up periods in many of the published clinical studies are considered relatively short to make a conclusive statement on the safety of ASCs. Therefore, having a surveillance system in place along with a rigorous follow-up or retrospective cohort studies will be crucial in identifying the long-term risk of ASCs.
On the other hand, there is concern regarding the use of culture-expanded ASCs, which may pose an additional risk of tumuorigenicity if these cells escape senescence, transform and progress to become tumuorigenic (Ref. This highlights the importance of strict compliance with manufacturing standards in handling and preparing ASCs as well as appropriate screening of cells before transplantation.
As observed, many countries recognise the advent of the cell therapy industry and have put regulatory frameworks in place to assure safety of cell administration to human recipients. However, there is still lack of universal protocols on the isolation of ASCs or SVF (Ref. 67) . Hence, deeper understanding on the characteristics of ASCs will be useful in refining the isolation and culturing procedures to assure their clinicalgrade quality. Furthermore, initiatives such as It is also essential that individual countries' regulatory guidelines will be designed to assure universal safety requirement of ASC-based therapy. Hence, countries considering loosening the regulatory framework for stem cell therapeutics should exercise caution as any serious adverse event in one country may potentially impede on credibility of approved cell-based therapy in all other countries. Consequently, more international collaboration would be necessary to implement global policies that safety and efficacy of ASCs are uniformly measured and shared across countries.
As ASC-based therapies are currently at the nascent stage of clinical trials, it is likely to take at least a few more years before ASCs are regarded as a standard regimen to treat some of the diseases. However, clinical trials with ASCs so far have shown promising results with notable absence of serious adverse events being reported to date. Most notably, cell therapies with ASCs in plastic and reconstructive procedures are already widely used as they offer higher aesthetically-acceptable results. Moreover, the regenerative and therapeutic secretory properties of ASCs are promising in relieving symptoms of chronic diseases, as supported by the studies previously done with bone marrowderived MSCs (Refs 132, 133) . Therefore, with more research efforts going into the study of ASCs in both scientific and clinical settings, ASCs may pave the way to novel clinical strategies and paradigms in treating a wide variety of diseases.
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